A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for Doxorubicin resistance - PubMed (original) (raw)

. 2002 Apr 15;62(8):2294-9.

Affiliations

PMID: 11956086

A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for Doxorubicin resistance

John D Allen et al. Cancer Res. 2002.

Abstract

The recent identification of mutations at arginine 482 (R482) in human Breast Cancer Resistance Protein (BCRP) in two drug-selected cell lines largely explains some discrepancies observed in the cross-resistance profiles of human cell lines overexpressing this multidrug transporter. We find that each of three mouse cell lines independently selected for resistance to the anthracycline doxorubicin also acquired mutations in the cognate mouse transporter Bcrp1 exclusively at R482. Although the mouse Bcrp1 amino acid substitutions (M or S) are distinct from those seen in the human cell lines (G or T), they all have similar consequences: (a) greater resistance to anthracyclines (and bisantrene); (b) relatively lower resistance to topotecan; (c) greatly enhanced efflux of the dye rhodamine 123. The ready selection of R482X mutations seen in vitro might also occur in tumors treated with anthracyclines. Thus, it is noteworthy that the efficacy of Bcrp1 inhibitors applicable in vivo was not markedly affected by the presence of the mutations. We found that the Bcrp1 mutations all occurred after previous amplification and overexpression of the wild-type gene under doxorubicin selection; wild-type Bcrp1 is evidently able to mediate substantial resistance to anthracyclines, and this was confirmed in Bcrp1-transduced cell lines. These observations emphasize the general importance of the arginine at amino acid 482 for substrate specificity of the transporter, while reminding us that unmutated Bcrp1 remains a potential source of resistance to anthracyclines and a potential factor in anthracycline pharmacokinetics. The same is most likely true of human BCRP, given its profound similarities to mouse Bcrp1.

PubMed Disclaimer

Cited by

The emerging pharmacotherapeutic significance of the breast cancer resistance protein (ABCG2).
Hardwick LJ, Velamakanni S, van Veen HW. Hardwick LJ, et al. Br J Pharmacol. 2007 May;151(2):163-74. doi: 10.1038/sj.bjp.0707218. Epub 2007 Mar 20. Br J Pharmacol. 2007. PMID: 17375082 Free PMC article. Review.
A functional study on polymorphism of the ATP-binding cassette transporter ABCG2: critical role of arginine-482 in methotrexate transport.
Mitomo H, Kato R, Ito A, Kasamatsu S, Ikegami Y, Kii I, Kudo A, Kobatake E, Sumino Y, Ishikawa T. Mitomo H, et al. Biochem J. 2003 Aug 1;373(Pt 3):767-74. doi: 10.1042/BJ20030150. Biochem J. 2003. PMID: 12741957 Free PMC article.
Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity.
Robey RW, Honjo Y, Morisaki K, Nadjem TA, Runge S, Risbood M, Poruchynsky MS, Bates SE. Robey RW, et al. Br J Cancer. 2003 Nov 17;89(10):1971-8. doi: 10.1038/sj.bjc.6601370. Br J Cancer. 2003. PMID: 14612912 Free PMC article.
In Vitro Comparison of the Role of P-Glycoprotein and Breast Cancer Resistance Protein on Direct Oral Anticoagulants Disposition.
Hodin S, Basset T, Jacqueroux E, Delezay O, Clotagatide A, Perek N, Mismetti P, Delavenne X. Hodin S, et al. Eur J Drug Metab Pharmacokinet. 2018 Apr;43(2):183-191. doi: 10.1007/s13318-017-0434-x. Eur J Drug Metab Pharmacokinet. 2018. PMID: 28895074
Pharmacogenetics of membrane transporters: a review of current approaches.
Sissung TM, Goey AK, Ley AM, Strope JD, Figg WD. Sissung TM, et al. Methods Mol Biol. 2014;1175:91-120. doi: 10.1007/978-1-4939-0956-8_6. Methods Mol Biol. 2014. PMID: 25150868 Free PMC article. Review.

A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for Doxorubicin resistance - PubMed (original) (raw)